New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news
Eating just one bag of chips each day may raise risk of throat and mouth cancers 25%, study suggests
A new study suggests that eating junk foods like pizza, chips and candies daily over the course of a decade can increase the risk of throat and mouth cancer - and it's not just because of weight gain (Source: the Mail online | Health)
Source: the Mail online | Health - November 23, 2023 Category: Consumer Health News Source Type: news
Four breakfast foods that could raise risk of mouth cancer after new study finding
Eating lots of ultra-processed foods could lead to mouth and throat cancers, a new study has revealed. (Source: Daily Express - Health)
Source: Daily Express - Health - November 22, 2023 Category: Consumer Health News Source Type: news
Obesity may not be the only factor to link ultra-processed foods to higher risk of mouth, throat and oesophagus cancers
Eating more ultra-processed foods (UPFs) may be associated with a higher risk of developing cancers of upper aerodigestive tract (including the mouth, throat and oesophagus), according to a new study led by researchers from the University of Bristol and the International Agency for Research on Cancer (IARC). (Source: University of Bristol news)
Source: University of Bristol news - November 22, 2023 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Institutes, Bristol Population Health Science Institute; Press Release Source Type: news
Redispensing Unused Cancer Meds Cuts Waste, Saves Money Redispensing Unused Cancer Meds Cuts Waste, Saves Money
Redispensing unused oral anticancer medications has the potential to improve sustainability and affordability of cancer treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer
(MedPage Today) -- The FDA approved repotrectinib (Augtyro) -- an oral tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions -- for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2023 Category: American Health Source Type: news
Dentist gives urgent warning over the earliest signs of mouth cancer to spot
Cases of mouth cancer have seen a 46 per cent rise over the last decade. (Source: Daily Express - Health)
Source: Daily Express - Health - November 12, 2023 Category: Consumer Health News Source Type: news
'I’m a dentist - here are four red flag signs of mouth cancer you should get checked'
Cases of the deadly disease have risen to a "record high" in the UK, with almost one person diagnosed every hour. (Source: Daily Express - Health)
Source: Daily Express - Health - November 11, 2023 Category: Consumer Health News Source Type: news
FDA Approves Fruquintinib for Metastatic Colorectal Cancer FDA Approves Fruquintinib for Metastatic Colorectal Cancer
This marks the first approval for the oral anti-VEGFR tyrosine kinase inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
